Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

The drug joins abemaciclib (Verzenio) as approved CDK4/6 inhibitors in this setting, but the broader indication for ...

1 Ribociclib is manufactured by Novartis for early breast cancer and advanced or metastatic breast cancer ... The primary efficacy outcome was measured by the invasive disease-free survival that led ...

The Food and Drug Administration approved ribociclib plus an aromatase inhibitor for hormone receptor (HR)–positive, ...

People who took Kisqali plus letrozole in the study had a median overall survival ... fulvestrant or placebo combined with fulvestrant for HR-positive, HER2-negative advanced or metastatic breast ...

KFF Health News, July 02, 2024 ASCO 2024 MUC-1 Vaccine Shows Notable Overall ... in Breast Cancer Abemaciclib plus fulvestrant improved progression-free survival in certain patients with advanced ...

In MBC, Kisqali has consistently demonstrated statistically significant overall survival benefit across three Phase III trials10-20. The NCCN Guidelines® for breast cancer recommend ribociclib ...

Basel, September 17, 2024 – Novartis today announced that the US Food and Drug Administration (FDA) has approved Kisqali ® (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant ...

including overall survival. "With this approval, we are redefining treatment options for a broader population of people impacted by breast cancer and facing the persistent risk of recurrence ...

Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhi ...